CAS 185991-07-5: 2-Pyridinemethanamine, N-[[4-(1,4,8,11-tetraazacyclotetradec-1-ylmethyl)phenyl]methyl]-, hydrobromide (1:6)

Applications AMD 3465 is a CXCR4 antagonist and in combination with monoclonal antibody, was shown to be potentially effective in reducing tumor growth and increasing survival in patient with B cell lymphoma References Burger, J.A., et al.: Leuke. Lympho.,53. 3 (2012); Lam, A.R., et al.: J. Chem. Info. Model., 51, 139 (2011); De Clercq. E., et al.: Pharmacol. Therap., 128. 509 (2010);

AMD 3465 hexahydrobromide

AMD 3465 hexahydrobromide (GENZ-644494 (hexahydrobromide)) is a CXCR4 receptor antagonist with potential anticancer and anti-HIV activity.

AMD 3465 is a potent CXCR4 antagonist, which is derived from small-molecule chemical synthesis. This compound functions by specifically targeting and binding to the CXC chemokine receptor 4 (CXCR4), thereby hindering the interaction between the receptor and its natural ligand, stromal-derived factor-1 (SDF-1 or CXCL12). By blocking this interaction, AMD 3465 effectively disrupts signaling pathways involved in cellular processes such as chemotaxis, proliferation, and survival. The primary applications of AMD 3465 are in the fields of oncology and virology. In cancer research, it holds promise for inhibiting tumor metastasis, as the CXCR4/CXCL12 axis is implicated in the dissemination and homing of malignant cells. Furthermore, it has potential in HIV research as the CXCR4 receptor is exploited by certain strains of the virus for cellular entry, thus AMD 3465 may act as a therapeutic agent in hindering viral infection. The ability of AMD 3465 to intervene in critical biochemical pathways makes it a significant subject of interest in the development of targeted therapies.